Diffusion Pharmaceuticals Net Income

The latest net income for DFFN is $-30M as of June 2026. That compares with $8.3B in the prior-year period — down 100.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Diffusion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, DFFN's net income moved from $8.3B to $-30M — a 100.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Diffusion Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, DFFN currently prints $-30M for net income, while the sector average sits near $16B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Diffusion Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-30M for DFFN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting DFFN's net income ($-30M), review year-over-year change from $8.3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.